AstraZeneca Pharmaceuticals LP lost its fight to block ANDAs of Crestor (rosuvastatin) that carve out patented indications of the cholesterol-lowering drug. Generic manufacturers will thus be able to launch their products when Crestor’s composition patent expires in 2016.
In a Feb. 9 decision, the U.S. Court of Appeals for the Federal Circuit affirmed a district court ruling that...